Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Jerry Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anna Marit de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan De Hoon, William Smith, Kathryn Stephenson, Dan Barouch, Stephen De Rosa, Kristen Cohen, Juliana McElrath, Emmanuel Cormier, Gert Scheper, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, Hanneke Schuitemaker
doi: https://doi.org/10.1101/2020.09.23.20199604
Jerry Sadoff
1 Janssen;
Mathieu Le Gars
2 Janssen Vaccines and Prevention;
Georgi Shukarev
1 Janssen;
Dirk Heerwegh
1 Janssen;
Carla Truyers
1 Janssen;
Anna Marit de Groot
1 Janssen;
Jeroen Stoop
1 Janssen;
Sarah Tete
1 Janssen;
Wim Van Damme
1 Janssen;
Isabel Leroux-Roels
3 CEVAC - University of Gent;
Pieter-Jan Berghmans
4 SGS Life Sciences;
Murray Kimmel
5 Optimal Research LLC;
Pierre Van Damme
6 CEV University of Antwerp;
Jan De Hoon
7 CCP LUVAC UZ Leuven;
William Smith
8 VRG and NOCCR;
Kathryn Stephenson
9 Beth Israel Deaconess Medical Center;
Dan Barouch
9 Beth Israel Deaconess Medical Center;
Stephen De Rosa
10 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
Kristen Cohen
10 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
Juliana McElrath
10 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
Emmanuel Cormier
1 Janssen;
Gert Scheper
1 Janssen;
Jenny Hendriks
1 Janssen;
Frank Struyf
1 Janssen;
Macaya Douoguih
1 Janssen;
Johan Van Hoof
1 Janssen;
Hanneke Schuitemaker
1 Janssen;

Data Availability
The data referred to in the manuscript will be available.
Posted September 25, 2020.
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Jerry Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anna Marit de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan De Hoon, William Smith, Kathryn Stephenson, Dan Barouch, Stephen De Rosa, Kristen Cohen, Juliana McElrath, Emmanuel Cormier, Gert Scheper, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, Hanneke Schuitemaker
medRxiv 2020.09.23.20199604; doi: https://doi.org/10.1101/2020.09.23.20199604
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Jerry Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anna Marit de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan De Hoon, William Smith, Kathryn Stephenson, Dan Barouch, Stephen De Rosa, Kristen Cohen, Juliana McElrath, Emmanuel Cormier, Gert Scheper, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, Hanneke Schuitemaker
medRxiv 2020.09.23.20199604; doi: https://doi.org/10.1101/2020.09.23.20199604
Subject Area
Subject Areas
- Addiction Medicine (62)
- Allergy and Immunology (142)
- Anesthesia (44)
- Cardiovascular Medicine (408)
- Dermatology (47)
- Emergency Medicine (141)
- Epidemiology (4810)
- Gastroenterology (177)
- Geriatric Medicine (70)
- Health Economics (187)
- Health Informatics (621)
- Health Policy (314)
- Hematology (85)
- HIV/AIDS (155)
- Medical Education (91)
- Medical Ethics (24)
- Nephrology (73)
- Neurology (677)
- Nursing (41)
- Nutrition (110)
- Oncology (438)
- Ophthalmology (138)
- Orthopedics (36)
- Otolaryngology (88)
- Pain Medicine (35)
- Palliative Medicine (15)
- Pathology (127)
- Pediatrics (193)
- Public and Global Health (1798)
- Radiology and Imaging (321)
- Respiratory Medicine (255)
- Rheumatology (86)
- Sports Medicine (61)
- Surgery (100)
- Toxicology (23)
- Transplantation (28)
- Urology (37)